US Trade Policy and Indian Pharmaceutical Sector Dynamics – Prelims Specific

Introduction

The pharmaceutical sector serves as a vital component of India's export-oriented economy. Potential protectionist measures by the United States regarding generic drug imports raise significant concerns for India's trade competitiveness, supply chain stability, and its status as a primary global supplier of affordable medicines.

Why in News?

• The incoming US administration has signaled potential broad tariff impositions on imported goods.
• This has triggered concerns regarding the impact on Indian pharmaceutical firms, which supply 30-40 percent of generic drugs consumed in the US market.
• The shift reflects a growing global trend toward economic nationalism and the reshoring of critical healthcare supply chains.

Static Link

• The issue relates to the External Sector of the economy, specifically Trade Barriers (Tariffs) and Balance of Payments (BoP).
• Protectionist measures by developed nations directly impact India's export growth and foreign exchange reserves.
• UPSC often examines how shifts in trade policy affect sector-specific dominance, particularly in industries where India holds a global comparative advantage.

Institutional Link

• Pharmaceuticals Export Promotion Council of India (Pharmexcil): A nodal agency under the Department of Commerce, Ministry of Commerce and Industry, dedicated to promoting pharmaceutical exports.
• US Food and Drug Administration (USFDA): A US regulatory body whose standards serve as a critical quality benchmark for international pharmaceutical exporters.
• World Trade Organization (WTO): The multilateral forum where international trade disputes are adjudicated, particularly those concerning trade-related aspects of intellectual property and tariff barriers.

Core Prelims Facts

• India is a global leader in generic medicine production due to cost-effective manufacturing and technical expertise.
• Indian pharmaceutical exports are a significant contributor to India’s services and manufacturing-linked export growth.
• A major structural weakness is the high dependency on imported Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs), often sourced from China.

Important Terms and Concepts

• Generic Drugs: Medications created to be the same as an already marketed brand-name drug in dosage form, safety, strength, route of administration, and quality.
• Active Pharmaceutical Ingredient (API): The biologically active component of a drug product that produces the intended health effect.
• Trade Barriers: Government-induced restrictions on international trade, such as tariffs or quotas, used to protect domestic industries.

Bodies / Organisations / Institutions

• Ministry of Commerce and Industry: Primary ministry for framing India's EXIM policy.
• Pharmexcil: Promotes pharmaceutical exports; functions under the Department of Commerce.
• CDSCO (Central Drugs Standard Control Organisation): India's national regulatory body for pharmaceuticals and medical devices, operating under the Ministry of Health and Family Welfare.

Schemes / Laws / Reports / Conventions

• Production Linked Incentive (PLI) Scheme for Pharmaceuticals: A government initiative aimed at boosting domestic manufacturing of bulk drugs and finished formulations to reduce import dependency.
• TRIPS Agreement: The WTO agreement on trade-related aspects of intellectual property rights that governs patent protections impacting generic drug production.

Possible UPSC Prelims Traps

• Misidentifying the ministry: Pharmexcil is under the Department of Commerce, not the Ministry of Health and Family Welfare.
• Regulatory confusion: USFDA approval is a voluntary quality standard for exporters, not a domestic Indian regulatory requirement.
• Absolute traps: Assuming tariffs will automatically lead to a total collapse of Indian exports or that India is entirely self-reliant for all raw materials.
• Institutional role: Confusing the role of CDSCO (Indian regulator) with that of USFDA (US regulator).

One-Minute Revision Notes

• India provides 30-40 percent of generic drugs used in the US.
• Pharmexcil is the nodal agency for pharma exports under the Ministry of Commerce.
• The PLI scheme is the primary Indian policy response to reduce API import dependency.
• Protectionism poses a risk to India’s export margins and global market share.

Practice MCQ for Prelims

1. Consider the following statements regarding the pharmaceutical sector in India:

1. The Pharmaceuticals Export Promotion Council of India (Pharmexcil) operates under the Ministry of Health and Family Welfare.

2. The Production Linked Incentive (PLI) scheme for pharmaceuticals aims to enhance domestic manufacturing of Active Pharmaceutical Ingredients (APIs).

Which of the statements given above is/are correct?

A. 1 only

B. 2 only

C. Both 1 and 2

D. Neither 1 nor 2

Answer: B

Explanation: Statement 1 is incorrect as Pharmexcil functions under the Department of Commerce, Ministry of Commerce and Industry. Statement 2 is correct as the PLI scheme aims to reduce import dependency for critical drug components.